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apy. Methods: Observational, non-interventional, prospective, single-center study 
of 1 year follow-up from ITB implant onward. Results: 20 consecutive patients with 
ITB indication were recruited; 13 received an ITB implant during the study period; 
1 implant was rejected and thus explanted. 12 patients, of whom 10 had spasticity 
due to spinal-cord injury, 1 to multiple sclerosis and 1 to adrenoleukodistrophy, pro-
vided data for the study and 9 completed follow-up. After 12 months of ITB, mean 
changes from baseline were: -2.6 on the Penn scale (p= 0.011), -1.1 (p= 0.059) and -2.8 
(p= 0.011) on the Ashworth upper and lower scale, respectively and +4.4 on the FIM 
scale (p= 0.075). Mean utility gain, assessed with the HUI3 scale, was 0.054 (p= 0.091) 
after 1 year. Mean total ITB test and permanent implant cost per patient were € 528 
and € 14,225, respectively. Mean quarterly spending on oral antispastics decreased 
by € 42 at month 12, while consumption of intrathecal baclofen stabilized after 6 
months at € 39. At baseline, 4 patients received botulinum injections, while none 
did at the end of follow-up. Catheter-related adverse events occurred in 2 out of 12 
patients, with a total mean cost per event of € 2.387. While waiting to receive ITB, 
spasticity-related hospitalizations due to urological complications occurred in 2 out of 
20 patients, with a mean cost of € 9.044 per event; no such events were observed after 
ITB implant. ConClusions: Clinical outcomes of patients with N-FDS improved 
after ITB. Initial therapy costs were considerable, but were partially offset by savings 
in drugs and spasticity-related events after 1 year follow-up. Results should be inter-
preted cautiously because of the small number of observations.
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objeCtives: Pseudobulbar Affect (PBA) is a neurologic disorder of emotional 
expression, resulting in frequent and involuntary episodes of crying and/or laugh-
ing. Common neurological conditions associated with PBA include: Alzheimer’s 
disease, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, stroke 
and traumatic brain injury. Nuedexta® (Avanir Pharmaceuticals Inc.) is the only 
EMA-approved PBA treatment. The financial impact of introducing Nuedexta to 
a national health care system, including Scotland, has never been formally esti-
mated. Methods: An Excel® based cost-calculator was developed. Prevalence, 
epidemiology and mortality estimates for causative neurological conditions as 
well as PBA prevalence in those conditions were sourced from the literature. Unit 
costs (drugs, hospitalisation etc.) were taken from national databases and standard 
care treatment mix and resource use were derived from a US claims database. A 
range of market uptake rates were used with further sensitivity analyses under-
taken. Results: The estimated cost of standard care in Scotland for PBA is circa 
£32.4 million annually (circa 22,500 patients). In year 1 following introduction, 67 
patients are expected to receive Nuedexta, resulting in a cost increase by £0.1 mil-
lion to £32.5 million. By year five, 836 patients are estimated to receive Nuedexta, 
resulting in a projected total annual cost of £34.6 million. Therefore the estimated 
annual budget impact of Nuedexta ranges from £0.15 million (year 1) to £1.88 mil-
lion (year 5). The incremental cost per patient is £2,246. The model was sensitive 
to changes in uptake rates, cost of background therapy and PBA symptom severity. 
When patients with moderate to severe PBA symptoms receive treatment, the pro-
jected cumulative year 5 budget impact estimate is £7.56 million. ConClusions: 
The estimated financial impact of introducing Nuedexta in Scotland is modest. Even 
if more patients are identified, the relatively small incremental cost per-patient of 
Nuedexta is unlikely to have a major impact on the Scottish NHS.
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objeCtives: To analyze factors of recent evolution of Multiple Sclerosis (MS) Disease 
Modifying Therapies (DMT) budgets in Spain between 2004 and 2013. Methods: 
2004-2013 single DMT monthly expenditure was provided by IMS Health. Monthly and 
annually evolution of number of patients, billing, drug cost per patient and cost per 
year of treatment were calculated. Two periods: 2004-2013 and 2007 (start marketing 
second lines DMT) -2013 period were analyzed for each DMT line. (First line: subcutane-
ous and intramuscular interferon (IFN) β -1a, subcutaneous IFN β -1b and glatiramer acetate 
injection. Second line: natalizumab and fingolimod). Results: During 2004-2013 DMT 
expenditure increased from € 115.5M to € 319.3M due to: A greater number of patients 
147% (10.60 % annual growth per year) and a further growth of annual cost per patient: 
12% (1.29 % annual growth per year). In December 2013 second lines correspond to 
a 29.61% of DMT expenditure. Annual cost per patient in second line represents 70% 
over cost per treated patient and 83% greater than first line DMT cost per year. If 
year 2007 is omitted from analysis (Only 68 second-line treatments and M1.44€ of 
associated expense) and is analyzed 2008-2013 period, second-line DMT represent 
43% of new treatments causing a 60% increase in DMT expenditure. In 2013 second 
line DMT participation reaches 64% of new regimens causing the 79% of increase DMT 
expenditure. ConClusions: The growing incorporation of new therapies and the 
noticeable rise in the number of treated patients (10.60 % annual growth per year) are 
components to consider in the pharmaceutical budget management.
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objeCtives: Comprehensive economic costs of multiple sclerosis (MS) accord-
ing to EDSS states can only be assessed by evaluating MS management in real 
clinical practice. The objective of this cross-sectional study was to measure the 
association of Khorasan privence (the widest province in Iran ). Quality of life was 
measured with MSQOL-54 instrument. Data was collected by employing a 32- item 
self-administered questionnaire in a face to face interview. Parametric, nonpara-
metric tests and descriptive statistics analysis were applied (p value< 0.05). Patients 
were grouped into three disability stages according to their Expanded Disability 
Scale Score (EDSS). Results: The Patients mean age was 31.78 (SD: 9.67 ) years, 
% 73.8 were female and %26.3 were male, and their mean EDSS was 2.4 (SD; 1.26) 
whereas EDSS increases, the costs also increases, which is a positive correlation. 
The mean QOL was 0.54 that as QOL increases, the costs decreases, which is a nega-
tive correlation. The MS medications (Interferon) have a cost around $ 46625 per 
year for each patient that are subsidized about $ 24452 IR by governmental sector. 
Up to $ 17104 are paid by insurance and $ 5263 directly by patients. The costs per 
patient-year were calculated as $ 11560) - 27970.5591 (EDSS= 1-2.5), $ 29916.909- 
30015.645 (EDSS= 3-4.5) and $34678.776- 34793.22 (EDSS= 5- 7.5). ConClusions: 
We conclude that the costs are relevant in MS, especially when disability increases. 
The catastrophic cost has a high burden to patients, society and health care system
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objeCtives: The primary objective of this study is to elucidate the effect of whole 
exome sequencing (WES) in diagnosing children with a developmental delay due to 
unexplained conditions presumed to be genetic. A secondary objective is to collect 
all resources used by these children to gain insight into the total costs over time for 
the traditional diagnostic pathway and the additional costs to diagnose a patient 
using WES. Methods: We included twenty children at the Sylvia Toth Centre (STC) 
in Utrecht, the Netherlands, who have underwent previously extensive clinical diag-
nostic workups and for whom no diagnosis was found after the last extensive workup. 
On all twenty children and parents WES will be performed, thereby obtaining a list 
of exonic candidate mutations for each patient. In parallel all resources used were 
collected by assessing the clinical records of patients. These resources were linked 
to unit costs to obtain the total cost per patient. Total cost per patient was then com-
pared to the cost of care using WES, assessed for each individual patient. Results: 
The diagnostic yield from the 13 patients sequenced thus far is 23% indicating a 23% 
increase in number of diagnoses compared to the current diagnostic pathway. On 
average these patients have had numerous visits to the hospital, overnight stays 
and different diagnostic workups to unravel the genetic cause of their neurologi-
cal disorder. Total cost of the current diagnostic pathway is therefore up to ten fold 
higher compared to the total cost of only providing WES. ConClusions: Comparing 
the diagnosis and costs with and without the use of WES gives a clear picture of the 
clinical and economic feasibility of putting WES into standard diagnostic practice at 
the STC and similar genetic centers over the world.
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objeCtives: To estimate the clinical and financial impact of Interferon beta-1a 
intramuscular (IM) and subcutaneous (SC) formulations in Portugal, based on the 
findings from Cochrane review regarding first-line treatments for relapsing-remit-
ting multiple sclerosis. Methods: An Excel-based model estimated the number of 
relapses and costs incurred by a hypothetical cohort of 1000 patients treated with 
two types of interferon beta-1a. The model evaluated the consequences of treatment 
with SC versus IM interferon beta-1a, as this was the only comparison whose data 
quality was assessed as ‘high’ by the Cochrane Review (Filippini 2013). Risk of relapse 
was based on the 2-year data from the Cochrane meta-analysis. The analysis was 
performed from a Portuguese National Health Service (NHS) perspective including 
only direct costs. Although efficacy was kept constant as Cochrane did not report 
outcomes based on Expanded Disability Status Scale (EDSS), costs of relapse were 
available for patients with different EDSS values, thus allowing estimation of cost 
impact for different types of population. Results: According to the model, treat-
ment with IM interferon beta-1a is expected to result in a total of 743 episodes of 
relapse, whereas SC interferon beta-1a is expected to result in a total of 570 cases, 
less 173 cases, over a 2-year period. Use of the SC formulation in a population with 
EDSS ≤ 3 will result in savings of € 690,213.04 over the 2-year period due to avoided 
relapses. In a more severe population, with EDSS between 3.5 and 4.5, these savings 
are expected to be € 889,865.74 over the same 2-year period. ConClusions: When 
compared with the IM formulation, the use of SC interferon beta-1a seems to be 
associated with fewer cases of relapse, resulting over a 2-year period in considerable 
potential savings to the NHS in terms of relapses avoided.
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objeCtives: To assess clinical outcomes, health care resource utilization and asso-
ciated costs of intrathecal baclofen therapy (ITB) for the treatment of non-focal 
disabling spasticity (N-FDS) in patients who are resistant or intolerant to oral ther-
